First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.

BACKGROUND

Epidermal growth factor receptor (EGFR) mutations in squamous cell lung carcinoma are rare. EGFR-tyrosine kinase inhibitors are generally less effective for EGFR-mutated squamous cell lung carcinoma. We herein present a case of EGFR-mutated squamous cell lung carcinoma that responded to osimertinib.

CASE

A 75-year-old woman with bloody sputum and left back pain was referred to NHO Kochi Hospital. A mass was observed in the left lower lobe on chest CT. Squamous cell lung carcinoma, cT4N1M1b (adrenal metastasis) stage IVA, was diagnosed based on the findings of a CT-guided percutaneous lung biopsy and a CT scan revealing right adrenal metastasis. The primary tumor was subjected to a genomic analysis with the AmoyDx Pan Lung Cancer PCR panel, which revealed an EGFR mutation (exon 21 L858R). The PD-L1 tumor proportion score was 95%. Osimertinib was initiated as first-line targeted therapy. Tumor shrinkage was observed and maintained over 9 months of treatment.

CONCLUSION

We encountered a rare EGFR-mutated squamous cell lung carcinoma that responded well to osimertinib. Osimertinib may be an option for the treatment of patients with EGFR-mutated squamous cell lung carcinoma.